Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Satigrel

Known as: 4-Pentenoic acid, 4-cyano-5,5-bis(4-methoxyphenyl)-, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
BACKGROUND Early and late vascular obstruction are both related to platelet adhesion and aggregation in the grafts. We assessed… Expand
Is this relevant?
1996
1996
Satigrel (E5510, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid) is a potent inhibitor of platelet aggregation. Like… Expand
Is this relevant?
1996
1996
OBJECTIVE Satigrel is a new antiplatelet agent which was previously shown to inhibit platelet aggregation and have an anti… Expand
Is this relevant?
1994
1994
A novel antiplatelet agent, satigrel (E5510), was administered to 9 patients with arteriosclerosis obliterans (ASO) and 6… Expand
Is this relevant?
1993
1993
E5510, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid, is a new anti-platelet-aggregation agent under development. We examined… Expand
Is this relevant?
1991
1991
The mode of action of E5510, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid, which has very potent anti-platelet activities… Expand
Is this relevant?
1990
1990
Non-heparin hemodialysis (HD) was successfully done in anuric dogs with the oral administration of a newly developed antiplatelet… Expand
Is this relevant?
1987
1987
Various pharmacological properties of a new antiplatelet aggregating agent, 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid (E… Expand
Is this relevant?